Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection within Approved Guidelines

STUDY OVERVIEW

This benchmarking study was conducted to understand how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines. The research examined a number of areas, including CI information sources and what is being collected. In addition, the study looked at how CI groups work with legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department’s ability to deliver results. Managers and executives in CI and CI-related groups can use this report to compare critical elements of their operations with those of leading firms.

KEY TOPICS

• Optimizing Data Collection - People, Processes & Practices
• Development & Examples of CI Guidelines
• Managing Expectations
• Rapid Response Teams
• Building a Successful CI Function

KEY METRICS

• Total Number of Marketed Brands Supported
• Number of Blockbuster Brands Supported
• Number of Pipeline Products Supported
• Number of Competitive Intelligence Full-Time Employees (FTEs)
• Effectiveness of Primary and Secondary Data Sources
• Effectiveness of Internal and External CI Data Collection Sources
• Effectiveness of Sources for Types of Information
• Formal Policies/Guidelines Governing CI Performance and Scope
• Functions Responsible for Guidelines Governing CI Operations
• Information Included in CI Guidelines
• Assessment of Guideline Impact on CI Function Productivity
• CI Guidelines Training
• CI Activities Ethical Assessments
• Rapid Response Team Utilization

METHODOLOGY